Zhuhai Shashi Biotechnology
Tumor-infiltrating lymphocyte (til) product being developed by the company for multiple indications.
Launch date
Employees
Market cap
-
Enterprise valuation
$220—330m (Dealroom.co estimates Sep 2023.)
China (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
$15.0m | Series A | ||
N/A | Series A | ||
* | CNY400m | Series B | |
Total Funding | $70.0m |